Ultragenyx Pharmaceutical Inc. — 2018 Form 10-K
Business context and period. The filing reports the fiscal year ended December 31, 2018; it is an annual report, not a standalone fourth-quarter filing. Ultragenyx develops and commercializes therapies for rare and ultra-rare genetic diseases. Crysvita and Mepsevii were approved products; the clinical pipeline included UX007, DTX301, DTX401 and DTX201. The audited financial statements received an unqualified opinion.
Financial performance and liquidity
| Metric | FY 2018 | FY 2017 |
|---|---|---|
| Total revenue | $51.5 million | $2.6 million |
| Product sales | $9.8 million | $0.5 million |
| Operating expenses | $422.9 million | $331.6 million |
| Loss from operations | $(371.4) million | $(328.9) million |
| Net loss | $(197.6) million | $(302.1) million |
| Net loss per share, basic and diluted | $(3.97) | $(7.12) |
| Cash used in operating activities | $(290.6) million | $(253.8) million |
- FY 2018 revenue included $41.7 million of collaboration and license revenue: $18.2 million from KHK/Crysvita and $23.5 million from Bayer. Product sales included $7.9 million of Mepsevii, $0.6 million of Crysvita and $1.3 million of UX007.
- Net loss included a $170.3 million gain from sales of priority review vouchers (PRVs). The Mepsevii voucher generated $130.0 million net proceeds; Crysvita’s $80.6 million net proceeds were shared equally with KHK. The gain reduced reported net loss but did not eliminate substantial operating losses.
- Fourth-quarter 2018 revenue was $16.3 million, operating expenses were $106.6 million, net loss was $87.8 million and basic and diluted loss per share was $1.73. Quarterly results included a first-quarter net profit of $30.3 million, reflecting the year’s unusual PRV gains.
- Research and development expense rose 27% to $294.0 million; selling, general and administrative expense rose 28% to $127.7 million. The filing does not provide a clear, decision-useful operating margin; reported product cost of sales was $1.1 million, and pre-approval manufacturing costs had been expensed rather than capitalized.
- Cash, cash equivalents and investments totaled $459.7 million at year-end, versus $244.5 million a year earlier; working capital was $447.6 million. Management said existing resources should fund projected operating needs for at least the next 12 months, while also anticipating a need for additional capital over time.
- Financing cash flow was $336.9 million, including $271.0 million net from an underwritten stock offering and $38.1 million net from ATM sales. Shares outstanding increased to 50.9 million from 44.2 million; further ATM capacity at year-end was $45.9 million.
- No borrowings or notes payable are listed on the year-end balance sheet; total liabilities were $110.7 million, including $31.2 million in deferred tax liabilities. Contractual operating lease and manufacturing/service commitments totaled $34.6 million. The company expected adoption of the new lease standard to add a right-of-use asset of $15.0–$18.4 million and lease liabilities of approximately $19.8–$24.2 million in 2019.
Material changes versus the prior period
- Revenue increased substantially as Crysvita received U.S. and EU approvals in 2018 and Mepsevii sales expanded following its 2017 approval. PRV gains and the full-year effect of the acquired Bayer collaboration also materially affected comparisons.
- Operating losses widened as R&D and commercial infrastructure spending increased. Higher investment in DTX301, DTX401 and DTX201 followed the 2017 Dimension acquisition; spending on discontinued Ace-ER declined.
- Operating cash use increased by $36.7 million year over year despite the lower reported net loss, which was principally affected by noncash PRV gains and other adjustments.
Outlook, commentary, risks and unusual items
- Management expected R&D and commercial spending to rise as pipeline programs advance and commercialization expands. No quantified revenue or earnings guidance was provided.
- Management planned to submit an NDA for UX007 in LC-FAOD in mid-2019, subject to regulatory discussions. DTX301 and DTX401 were advancing in Phase 1/2 dose cohorts, with additional data expected around mid-2019. Crysvita regulatory decisions in Latin America were anticipated by year-end 2019; the company was still discussing a potential TIO filing with the FDA.
- Ultragenyx discontinued UX007 development for Glut1 DS after a Phase 3 study failed its primary and key secondary endpoints. The filing also describes prior failure of Ace-ER Phase 3 studies and discontinuation of that program.
- Gene therapy remains early-stage and uncertain. DTX301 and DTX401 had small initial cohorts; mild ALT elevations were reported and managed with steroids. Rare-disease trial enrollment, endpoint validity, regulatory outcomes, manufacturing scale-up and long-term safety remain material uncertainties.
- Manufacturing and collaboration concentration are significant: KHK supplies Crysvita and controls key commercialization activities, while the company relies on third parties for product and candidate manufacturing. KHK and Bayer accounted for 35% and 46%, respectively, of FY 2018 total revenues, according to the filing.
- Other key risks include continued losses and potential financing needs, dilution from equity issuance, uncertain reimbursement and pricing, competition, intellectual-property challenges, and dependence on a small number of rare-disease patients. The company reported no material legal proceedings and no impairment of goodwill or acquired intangible assets in 2018.
Important facts for investors to verify
- How much of future revenue comes from recurring product sales and Crysvita collaboration economics, versus milestone/service revenue and one-time PRV proceeds?
- Whether commercial uptake, patient identification, reimbursement and supply support growth in Crysvita and Mepsevii, and how the KHK profit-share and transition terms affect Ultragenyx’s economics.
- Whether UX007’s planned NDA pathway is accepted and whether its clinical evidence supports approval; whether gene therapy results persist in larger, longer-term studies and remain acceptably safe.
- How quickly cash is consumed as operating cash use rises, and whether additional financing will be needed before the business can reduce losses.
- Whether manufacturing transitions—including Mepsevii’s planned drug-product site transfer—and reliance on single-source suppliers create delays, added costs or supply constraints.